BRISTOL-MYERS SQUIBB COMPANY Payments to Acquire Marketable Securities
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Payments to Acquire Marketable Securities of $2.85 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY payments to acquire marketable securities for the quarter ending 2026-06-30 was $2.07B, a 233.33% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY payments to acquire marketable securities for the quarter ending 2026-03-31 was $781.00M, a 22.80% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY payments to acquire marketable securities for the quarter ending 2025-12-31 was $78.00M, a 78.98% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY payments to acquire marketable securities for the quarter ending 2025-09-30 was $665.00M, a 1562.50% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY payments to acquire marketable securities for fiscal 2025 was $2.00B, a 160.08% increase from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY payments to acquire marketable securities for fiscal 2024 was $769.00M, a 56.65% decline from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY payments to acquire marketable securities for fiscal 2023 was $1.77B, a 50.61% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY payments to acquire marketable securities for fiscal 2022 was $3.59B, a 34.43% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month | Payments to Acquire Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $2.07B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $2.85B 10-Q · filed 2026-07-30 | $2.93B derived: sum of 3 quarters · filed 2026-07-30 | $3.59B derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $781.00M 10-Q · filed 2026-04-30 | $859.00M derived: sum of 2 quarters · filed 2026-04-30 | $1.52B derived: sum of 3 quarters · filed 2026-04-30 | $2.15B derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $78.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $743.00M derived: sum of 2 quarters · filed 2026-02-11 | $1.36B derived: sum of 3 quarters · filed 2026-07-30 | $2.00B 10-K · filed 2026-02-11 | |
| 2025-09-30 | $665.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.29B derived: sum of 2 quarters · filed 2026-07-30 | $1.92B 10-Q · filed 2025-10-30 | $2.29B derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $621.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.26B 10-Q · filed 2026-07-30 | $1.63B derived: sum of 3 quarters · filed 2026-07-30 | $1.67B derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $636.00M 10-Q · filed 2026-04-30 | $1.01B derived: sum of 2 quarters · filed 2026-04-30 | $1.05B derived: sum of 3 quarters · filed 2026-04-30 | $1.13B derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $371.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $411.00M derived: sum of 2 quarters · filed 2026-02-11 | $495.00M derived: sum of 3 quarters · filed 2026-02-11 | $769.00M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $40.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $124.00M derived: sum of 2 quarters · filed 2025-10-30 | $398.00M 10-Q · filed 2025-10-30 | $1.11B derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-06-30 | $84.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $358.00M 10-Q · filed 2025-07-31 | $1.07B derived: sum of 3 quarters · filed 2026-02-11 | $1.58B derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-03-31 | $274.00M 10-Q · filed 2025-04-24 | $991.00M derived: sum of 2 quarters · filed 2026-02-11 | $1.49B derived: sum of 3 quarters · filed 2026-02-11 | $1.85B derived: sum of 4 quarters · filed 2026-02-11 | |
| 2023-12-31 | $717.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.22B derived: sum of 2 quarters · filed 2026-02-11 | $1.57B derived: sum of 3 quarters · filed 2026-02-11 | $1.77B 10-K · filed 2026-02-11 | |
| 2023-09-30 | $502.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $857.00M derived: sum of 2 quarters · filed 2024-10-31 | $1.06B 10-Q · filed 2024-10-31 | $1.08B derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-06-30 | $355.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-26 | $555.00M 10-Q · filed 2024-07-26 | $581.00M derived: sum of 3 quarters · filed 2025-02-12 | $855.00M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-03-31 | $200.00M 10-Q · filed 2024-04-25 | $226.00M derived: sum of 2 quarters · filed 2025-02-12 | $500.00M derived: sum of 3 quarters · filed 2025-02-12 | $2.08B derived: sum of 4 quarters · filed 2025-02-12 | |
| 2022-12-31 | $26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $300.00M derived: sum of 2 quarters · filed 2025-02-12 | $1.88B derived: sum of 3 quarters · filed 2025-02-12 | $3.59B 10-K · filed 2025-02-12 | |
| 2022-09-30 | $274.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $1.85B derived: sum of 2 quarters · filed 2023-10-26 | $3.57B 10-Q · filed 2023-10-26 | $5.64B derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-06-30 | $1.58B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-27 | $3.29B 10-Q · filed 2023-07-27 | $5.36B derived: sum of 3 quarters · filed 2024-02-13 | $6.43B derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-03-31 | $1.71B 10-Q · filed 2023-04-27 | $3.78B derived: sum of 2 quarters · filed 2024-02-13 | $4.85B derived: sum of 3 quarters · filed 2024-02-13 | $5.89B derived: sum of 4 quarters · filed 2024-02-13 | |
| 2021-12-31 | $2.07B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $3.13B derived: sum of 2 quarters · filed 2024-02-13 | $4.18B derived: sum of 3 quarters · filed 2024-02-13 | $5.48B 10-K · filed 2024-02-13 | |
| 2021-09-30 | $1.06B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | $2.11B derived: sum of 2 quarters · filed 2022-10-26 | $3.41B 10-Q · filed 2022-10-26 | $4.43B derived: sum of 4 quarters · filed 2023-02-14 | |
| 2021-06-30 | $1.04B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $2.34B 10-Q · filed 2022-07-27 | $3.37B derived: sum of 3 quarters · filed 2023-02-14 | $4.56B derived: sum of 4 quarters · filed 2023-02-14 | |
| 2021-03-31 | $1.30B 10-Q · filed 2022-04-29 | $2.33B derived: sum of 2 quarters · filed 2023-02-14 | $3.52B derived: sum of 3 quarters · filed 2023-02-14 | $4.74B derived: sum of 4 quarters · filed 2023-02-14 | |
| 2020-12-31 | $1.02B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $2.21B derived: sum of 2 quarters · filed 2023-02-14 | $3.44B derived: sum of 3 quarters · filed 2023-02-14 | $4.17B 10-K · filed 2023-02-14 | |
| 2020-09-30 | $1.19B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $2.41B derived: sum of 2 quarters · filed 2021-10-27 | $3.15B 10-Q · filed 2021-10-27 | $5.47B derived: sum of 4 quarters · filed 2022-02-09 | |
| 2020-06-30 | $1.22B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | $1.96B 10-Q · filed 2021-07-28 | $4.28B derived: sum of 3 quarters · filed 2022-02-09 | $5.48B derived: sum of 4 quarters · filed 2022-02-09 | |
| 2020-03-31 | $735.00M 10-Q · filed 2021-04-29 | $3.05B derived: sum of 2 quarters · filed 2022-02-09 | $4.26B derived: sum of 3 quarters · filed 2022-02-09 | $4.45B derived: sum of 4 quarters · filed 2022-02-09 | |
| 2019-12-31 | $2.32B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $3.52B derived: sum of 2 quarters · filed 2022-02-09 | $3.72B derived: sum of 3 quarters · filed 2022-02-09 | $3.96B 10-K · filed 2022-02-09 | |
| 2019-09-30 | $1.21B derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.40B derived: sum of 2 quarters · filed 2020-11-05 | $1.64B 10-Q · filed 2020-11-05 | $2.88B derived: sum of 4 quarters · filed 2021-02-10 | |
| 2019-06-30 | $195.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $437.00M 10-Q · filed 2020-08-06 | $1.68B derived: sum of 3 quarters · filed 2021-02-10 | $2.29B derived: sum of 4 quarters · filed 2021-02-10 | |
| 2019-03-31 | $242.00M 10-Q · filed 2020-05-07 | $1.49B derived: sum of 2 quarters · filed 2021-02-10 | $2.10B derived: sum of 3 quarters · filed 2021-02-10 | $2.26B derived: sum of 4 quarters · filed 2021-02-10 | |
| 2018-12-31 | $1.24B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $1.86B derived: sum of 2 quarters · filed 2021-02-10 | $2.02B derived: sum of 3 quarters · filed 2021-02-10 | $2.31B 10-K · filed 2021-02-10 | |
| 2018-09-30 | $615.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $777.00M derived: sum of 2 quarters · filed 2019-10-31 | $1.06B 10-Q · filed 2019-10-31 | $2.05B derived: sum of 4 quarters · filed 2020-02-24 | |
| 2018-06-30 | $162.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25 | $447.00M 10-Q · filed 2019-07-25 | $1.43B derived: sum of 3 quarters · filed 2020-02-24 | $2.83B derived: sum of 4 quarters · filed 2020-02-24 | |
| 2018-03-31 | $285.00M 10-Q · filed 2019-04-25 | $1.27B derived: sum of 2 quarters · filed 2020-02-24 | $2.66B derived: sum of 3 quarters · filed 2020-02-24 | $4.50B derived: sum of 4 quarters · filed 2020-02-24 | |
| 2017-12-31 | $985.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $2.38B derived: sum of 2 quarters · filed 2020-02-24 | $4.21B derived: sum of 3 quarters · filed 2020-02-24 | $5.42B 10-K · filed 2020-02-24 | $5.44B 10-K · filed 2018-02-13 |
| 2017-09-30 | $1.39B derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $3.23B derived: sum of 2 quarters · filed 2018-10-25 | $4.43B 10-Q · filed 2018-10-25 | $5.28B derived: sum of 4 quarters · filed 2019-02-25 | |
| 2017-06-30 | $1.84B derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $3.04B 10-Q · filed 2018-07-26 | $3.88B derived: sum of 3 quarters · filed 2019-02-25 | $4.93B derived: sum of 4 quarters · filed 2019-02-25 | |
| 2017-03-31 | $1.20B 10-Q · filed 2018-04-26 | $2.04B derived: sum of 2 quarters · filed 2019-02-25 | $3.10B derived: sum of 3 quarters · filed 2019-02-25 | $3.77B derived: sum of 4 quarters · filed 2019-02-25 | |
| 2016-12-31 | $841.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $1.89B derived: sum of 2 quarters · filed 2019-02-25 | $2.57B derived: sum of 3 quarters · filed 2019-02-25 | $3.09B 10-K · filed 2019-02-25 | |
| 2016-09-30 | $1.05B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $1.73B derived: sum of 2 quarters · filed 2017-10-26 | $2.25B 10-Q · filed 2017-10-26 | $3.11B derived: sum of 4 quarters · filed 2018-02-13 | |
| 2016-06-30 | $672.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $1.20B 10-Q · filed 2017-07-27 | $2.06B derived: sum of 3 quarters · filed 2018-02-13 | $2.87B derived: sum of 4 quarters · filed 2018-02-13 | |
| 2016-03-31 | $523.00M 10-Q · filed 2017-04-27 | $1.38B derived: sum of 2 quarters · filed 2018-02-13 | $2.19B derived: sum of 3 quarters · filed 2018-02-13 | $2.85B derived: sum of 4 quarters · filed 2018-02-13 | |
| 2015-12-31 | $860.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $1.67B derived: sum of 2 quarters · filed 2018-02-13 | $2.32B derived: sum of 3 quarters · filed 2018-02-13 | $3.14B 10-K · filed 2018-02-13 | |
| 2015-09-30 | $811.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | $1.46B derived: sum of 2 quarters · filed 2016-10-27 | $2.28B 10-Q · filed 2016-10-27 | $3.19B derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-06-30 | $651.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $1.47B 10-Q · filed 2016-07-28 | $2.38B derived: sum of 3 quarters · filed 2017-02-21 | $4.18B derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-03-31 | $821.00M 10-Q · filed 2016-04-28 | $1.73B derived: sum of 2 quarters · filed 2017-02-21 | $3.53B derived: sum of 3 quarters · filed 2017-02-21 | $5.46B derived: sum of 4 quarters · filed 2017-02-21 | |
| 2014-12-31 | $908.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $2.71B derived: sum of 2 quarters · filed 2017-02-21 | $4.64B derived: sum of 3 quarters · filed 2017-02-21 | $5.72B 10-K · filed 2017-02-21 | |
| 2014-09-30 | $1.80B derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | $3.73B derived: sum of 2 quarters · filed 2015-10-27 | $4.81B 10-Q · filed 2015-10-27 | $5.22B derived: sum of 4 quarters · filed 2016-02-12 | |
| 2014-06-30 | $1.93B derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-23 | $3.01B 10-Q · filed 2015-07-23 | $3.42B derived: sum of 3 quarters · filed 2016-02-12 | $4.02B derived: sum of 4 quarters · filed 2016-02-12 | |
| 2014-03-31 | $1.08B 10-Q · filed 2015-04-28 | $1.49B derived: sum of 2 quarters · filed 2016-02-12 | $2.09B derived: sum of 3 quarters · filed 2016-02-12 | $2.66B derived: sum of 4 quarters · filed 2016-02-12 | |
| 2013-12-31 | $411.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $1.01B derived: sum of 2 quarters · filed 2016-02-12 | $1.58B derived: sum of 3 quarters · filed 2016-02-12 | $1.86B 10-K · filed 2016-02-12 | |
| 2013-09-30 | $598.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-24 | $1.17B derived: sum of 2 quarters · filed 2014-10-24 | $1.45B 10-Q · filed 2014-10-24 | $1.55B derived: sum of 4 quarters · filed 2015-02-13 | |
| 2013-06-30 | $572.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-24 | $850.00M 10-Q · filed 2014-07-24 | $956.00M derived: sum of 3 quarters · filed 2015-02-13 | $1.03B derived: sum of 4 quarters · filed 2015-02-13 | |
| 2013-03-31 | $278.00M 10-Q · filed 2014-04-29 | $384.00M derived: sum of 2 quarters · filed 2015-02-13 | $459.00M derived: sum of 3 quarters · filed 2015-02-13 | $1.27B derived: sum of 4 quarters · filed 2015-02-13 | |
| 2012-12-31 | $106.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $181.00M derived: sum of 2 quarters · filed 2015-02-13 | $992.00M derived: sum of 3 quarters · filed 2015-02-13 | $3.61B 10-K · filed 2015-02-13 | |
| 2012-09-30 | $75.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-23 | $886.00M derived: sum of 2 quarters · filed 2013-10-23 | $3.50B 10-Q · filed 2013-10-23 | $4.98B derived: sum of 4 quarters · filed 2014-02-14 | |
| 2012-06-30 | $811.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $3.43B 10-Q · filed 2013-07-25 | $4.90B derived: sum of 3 quarters · filed 2014-02-14 | $6.06B derived: sum of 4 quarters · filed 2014-02-14 | |
| 2012-03-31 | $2.62B 10-Q · filed 2013-04-25 | $4.09B derived: sum of 2 quarters · filed 2014-02-14 | $5.25B derived: sum of 3 quarters · filed 2014-02-14 | $7.20B derived: sum of 4 quarters · filed 2014-02-14 | |
| 2011-12-31 | $1.48B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14 | $2.63B derived: sum of 2 quarters · filed 2014-02-14 | $4.58B derived: sum of 3 quarters · filed 2014-02-14 | $6.82B 10-K · filed 2014-02-14 | |
| 2011-09-30 | $1.16B derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $3.11B derived: sum of 2 quarters · filed 2012-10-24 | $5.34B 10-Q · filed 2012-10-24 | $7.46B derived: sum of 4 quarters · filed 2013-02-15 | |
| 2011-06-30 | $1.95B derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $4.19B 10-Q · filed 2012-07-25 | $6.31B derived: sum of 3 quarters · filed 2013-02-15 | $6.42B derived: sum of 4 quarters · filed 2013-02-15 | |
| 2011-03-31 | $2.23B 10-Q · filed 2012-04-26 | $4.35B derived: sum of 2 quarters · filed 2013-02-15 | $4.47B derived: sum of 3 quarters · filed 2013-02-15 | $5.18B derived: sum of 4 quarters · filed 2013-02-15 | |
| 2010-12-31 | $2.12B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $2.24B derived: sum of 2 quarters · filed 2013-02-15 | $2.94B derived: sum of 3 quarters · filed 2013-02-15 | $5.82B 10-K · filed 2013-02-15 | |
| 2010-09-30 | $116.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $823.00M derived: sum of 2 quarters · filed 2011-10-27 | $3.70B 10-Q · filed 2011-10-27 | $4.87B derived: sum of 4 quarters · filed 2012-02-17 | |
| 2010-06-30 | $707.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $3.59B 10-Q · filed 2011-07-28 | $4.76B derived: sum of 3 quarters · filed 2012-02-17 | $5.16B derived: sum of 4 quarters · filed 2012-02-17 | |
| 2010-03-31 | $2.88B 10-Q · filed 2011-04-28 | $4.05B derived: sum of 2 quarters · filed 2012-02-17 | $4.46B derived: sum of 3 quarters · filed 2012-02-17 | $5.50B derived: sum of 4 quarters · filed 2012-02-17 | |
| 2009-12-31 | $1.17B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $1.58B derived: sum of 2 quarters · filed 2012-02-17 | $2.62B derived: sum of 3 quarters · filed 2012-02-17 | $3.49B 10-K · filed 2012-02-17 | |
| 2009-09-30 | $405.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $1.45B derived: sum of 2 quarters · filed 2010-10-26 | $2.32B 10-Q · filed 2010-10-26 | $2.49B derived: sum of 4 quarters · filed 2011-02-18 | |
| 2009-06-30 | $1.04B derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-22 | $1.91B 10-Q · filed 2010-07-22 | $2.09B derived: sum of 3 quarters · filed 2011-02-18 | $2.01B derived: sum of 4 quarters · filed 2011-02-18 | |
| 2009-03-31 | $870.00M 10-Q · filed 2010-04-29 | $1.04B derived: sum of 2 quarters · filed 2011-02-18 | $969.00M derived: sum of 3 quarters · filed 2011-02-18 | ||
| 2008-12-31 | $174.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $99.00M derived: sum of 2 quarters · filed 2011-02-18 | $422.00M 10-K · filed 2011-02-18 | ||
| 2008-09-30 | -$75.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-22 | $248.00M 10-Q · filed 2009-10-22 | |||
| 2008-06-30 | $323.00M 10-Q · filed 2009-07-23 | ||||
| 2007-12-31 | $19.88B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |